NCT03713645View on ClinicalTrials.gov

Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

May 23, 2021

Study Completion Date

January 31, 2022

Conditions
Kidney Transplant
Interventions
DRUG

Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant

Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals
All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Temple University

OTHER